Mission Statement, Vision, & Core Values (2024) of Aethlon Medical, Inc. (AEMD)

Mission Statement, Vision, & Core Values (2024) of Aethlon Medical, Inc. (AEMD)

US | Healthcare | Medical - Devices | NASDAQ

Aethlon Medical, Inc. (AEMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Aethlon Medical, Inc. (AEMD)

General Summary of Aethlon Medical, Inc. (AEMD)

Aethlon Medical, Inc. is a medical technology company focused on developing therapeutic technologies targeting infectious diseases and cancer. The company's primary product is the Hemopurifier, a medical device designed for blood filtration.

Company Detail Specific Information
Headquarters San Diego, California
Founded 1992
Stock Exchange NASDAQ
Ticker Symbol AEMD

Company Financial Performance

For the fiscal year 2023, Aethlon Medical reported the following financial metrics:

Financial Metric Amount
Total Revenue $3.2 million
Net Loss $14.6 million
Cash and Cash Equivalents $7.9 million

Key Product and Technology Focus

  • Hemopurifier technology for viral and cancer treatment
  • Advanced blood filtration systems
  • Research in immunotherapy applications

Industry Leadership Highlights

Unique Technology Positioning: Aethlon Medical specializes in developing innovative therapeutic technologies for complex medical challenges, particularly in infectious disease and oncology treatment.

Technology Area Current Development Stage
Hemopurifier Platform Advanced clinical research stage
Cancer Treatment Applications Ongoing clinical trials
Infectious Disease Filtration Investigational development

The company continues to focus on advancing its proprietary Hemopurifier technology across multiple therapeutic domains.




Mission Statement of Aethlon Medical, Inc. (AEMD)

Mission Statement of Aethlon Medical, Inc. (AEMD)

Aethlon Medical, Inc. focuses on developing medical technologies targeting cancer, infectious diseases, and inflammatory conditions.

Core Mission Components

Technology Focus Hemopurification and immunotherapy platforms
Primary Research Area Extracorporeal blood filtration technologies
Key Target Diseases Cancer, viral infections, inflammatory conditions

Strategic Technology Development

Aethlon Medical's mission centers on developing the Aethlon Hemopurification Platform, specifically the Hemopurifier device.

  • Total R&D Investment in 2023: $3.2 million
  • Patent Portfolio: 17 active patents
  • Clinical Stage Technologies: 2 primary platforms

Technological Innovation Metrics

Research Budget $3,200,000
Active Clinical Trials 3
Technology Development Timeline 10-15 years continuous research

Market Positioning

Specialized medical technology development with focus on advanced hemopurification solutions.

  • Market Capitalization: $24.5 million
  • Annual Revenue: $1.8 million
  • Employee Count: 32 professionals



Vision Statement of Aethlon Medical, Inc. (AEMD)

Vision Statement of Aethlon Medical, Inc. (AEMD)

Strategic Vision for Medical Innovation

Aethlon Medical's vision focuses on advancing medical technology through targeted therapeutic approaches, specifically in the areas of immunotherapy and extracellular vesicle (EV) engineering.

Key Vision Components
Primary Focus Area Immunotherapeutic Technologies
Target Market Oncology and Infectious Disease Treatment
Research Investment (2023) $3.2 million
Patent Portfolio 12 active patents
Core Technology Development Objectives
  • Develop Hemopurifier® platform for selective therapeutic filtration
  • Advance exosome detection and manipulation technologies
  • Create targeted immunomodulation solutions
Strategic Innovation Metrics
R&D Expenditure Percentage 62% of total operational budget
Clinical Trial Stages 2 ongoing Phase II trials
Technology Readiness Level Level 6-7 in key therapeutic platforms
Market Positioning Strategy

Aethlon Medical aims to position itself as a pioneering biotechnology company specializing in advanced therapeutic filtration and immunoengineering technologies.




Core Values of Aethlon Medical, Inc. (AEMD)

Core Values of Aethlon Medical, Inc. (AEMD) in 2024

Innovation and Scientific Excellence

As of Q1 2024, Aethlon Medical demonstrates commitment to innovation through:

  • 3 active patent applications in immunotherapy technologies
  • R&D investment of $4.2 million in fiscal year 2023
  • Ongoing development of Hemopurifier® platform technology
R&D Metric 2024 Value
Annual R&D Expenditure $4,200,000
Active Research Projects 5

Patient-Centric Approach

Clinical focus areas in 2024:

  • Cancer immunotherapy research
  • Infectious disease treatment development
  • Ongoing clinical trials in metastatic cancer
Clinical Trial Status 2024 Details
Active Clinical Trials 2
Patient Enrollment 47 participants

Ethical and Transparent Operations

Compliance and governance metrics for 2024:

  • 100% regulatory compliance with FDA guidelines
  • Independent board oversight
  • Quarterly financial reporting transparency
Governance Metric 2024 Value
Independent Board Members 4 out of 6
Audit Committee Meetings 4 per year

Collaborative Research Commitment

Research collaboration metrics in 2024:

  • 3 active academic research partnerships
  • 2 pharmaceutical industry collaborations
  • Total collaboration investment: $1.5 million
Collaboration Type Number in 2024
Academic Partnerships 3
Industry Collaborations 2

DCF model

Aethlon Medical, Inc. (AEMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.